Hyperthyroidism Clinical Trials

Find Hyperthyroidism Clinical Trials Near You

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid Drugs

Status: Recruiting
Location: See all (42) locations...
Intervention Type: Biological, Other
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody levels, and how the immune system responds to it. The study consists of a part A double-blinded treatment period, a part B treatment/observation period and a part C open-label treatment/observation period. During the part A and part B treatment periods, participants will receive efgartigimod PH20 SC via Prefilled Syringe (PFS) or placebo. During the part C open-label treatment period, participants will receive efgartigimod PH20 SC PFS. Participation in the different parts of the study will depend on the participant's response to treatment. The total study duration for participants ranges from 63 to 135 weeks, depending on the response to treatment. More information can be found here: https://clinicaltrials.argenx.com/vitalithy

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Is at least 18 years of age and the local legal age of consent for clinical studies when signing the ICF.

• Has a documented diagnosis of GD with TRAb (anti-thyrotropin receptor antibody) levels \>=ULN (upper limit of normal) at screening

• Has active hyperthyroidism due to GD with TSH (thyroid-stimulating hormone) \<0.1 mIU/L at screening

• Has been treated with MMI (methimazole) or CBZ (carbimazole) for at least 3 months before screening

Locations
Other Locations
Belgium
AZORG Ziekenhuis
RECRUITING
Aalst
Universitair Ziekenhuis Gent
RECRUITING
Ghent
Bulgaria
Medical Center Tonus - 2013 OOD
RECRUITING
Pazardzhik
DCC Pulmed
RECRUITING
Plovdiv
Multiprofile Hospital for Active Treatment Hadzhi Dimitar OOD
RECRUITING
Sliven
Medical Center Kalimat
RECRUITING
Sofia
Diagnostic Consultative Center Ekvita OOD
RECRUITING
Varna
MC Klinika Nova
RECRUITING
Varna
Multi-Profile District Hospital for Active Treatment Dr. Stefan Cherkezov
RECRUITING
Veliko Tarnovo
Canada
Endocrinologie Oasis
RECRUITING
Montreal
TLC Diabetes and Endocrinology Clinic
RECRUITING
Surrey
Denmark
Nordsjaellands Hospital - Hillerod
RECRUITING
Hillerød
Georgia
High Technology Hospital Medcenter LLC
RECRUITING
Batumi
First Medical Clinic Ltd
RECRUITING
Tbilisi
LTD MediClub Georgia
RECRUITING
Tbilisi
Germany
Institut fuer Praeventive Medizin & Klinische Forschung
RECRUITING
Magdeburg
Japan
Juntendo University Hospital
RECRUITING
Bunkyō-ku
Aso Iizuka Hospital
RECRUITING
Iizuka
Nippon Medical School Musashikosugi Hospital
RECRUITING
Kawasaki
Hospital of University of Occupational and Environmental Health
RECRUITING
Kitakyushu
National Hospital Organization Kyoto Medical Center
RECRUITING
Kyoto
Nagasaki University Hospital
RECRUITING
Nagasaki
Okayama University Hospital
RECRUITING
Okayama
Toho University Omori Medical Center
RECRUITING
Ōta-ku
Ito Hospital
RECRUITING
Shibuya City
SHOWA Medical University Northern Yokohama Hospital
RECRUITING
Yokohama
Tottori University Hospital
RECRUITING
Yonago
Latvia
LTD M & M Centers
RECRUITING
Adazi
Lithuania
Hospital of Lithuanian University of Health Sciences Kaunas
RECRUITING
Kaunas
Klaipeda's University Hospital
RECRUITING
Klaipėda
Poland
Centrum Medyczne INTERCOR Sp. z o.o.
RECRUITING
Bydgoszcz
DIABET Centrum Medyczne s.c.
RECRUITING
Chrzanów
NZOZ Holsamed- Oddzial Libero
RECRUITING
Katowice
Osrodek Medyczny Osteomed
RECRUITING
Krakow
Reumed Sp Z O.O.
RECRUITING
Lublin
Etg Warszawa Sp. z o.o.
RECRUITING
Warsaw
ETC Zamosc
RECRUITING
Zamość
Romania
Clinical Hospital of Emergency Sibiu Ambulatory if Endocrinology
RECRUITING
Sibiu
Spain
Hospital Universitario De La Ribera
RECRUITING
Alzira
Hospital de la Santa Creu i Sant Pau
RECRUITING
Barcelona
Instituto De Investigacion Marques De Valdecilla (IDIVAL
RECRUITING
Santander
Universidad de Sevilla - Hospital Universitario Virgen Macarena
RECRUITING
Seville
Contact Information
Primary
Sabine Coppieters, MD
clinicaltrials@argenx.com
857-350-4834
Time Frame
Start Date: 2026-06-10
Estimated Completion Date: 2030-05
Participants
Target number of participants: 230
Treatments
Experimental: Part A - efgartigimod PH20 SC PFS
Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period.
Placebo_comparator: Part A - placebo PH20 SC PFS
Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period.
Experimental: Part B - efgartigimod PH20 SC PFS
Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period.
Experimental: Part B - placebo PH20 SC PFS
Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period.
Experimental: Part C - efgartigimod PH20 SC PFS
Participants, will receive efgartigimod PH20 SC PFS in the part C open-label treatment period
Related Therapeutic Areas
Sponsors
Leads: argenx

This content was sourced from clinicaltrials.gov

Similar Clinical Trials